A retrospective study of bevacizumab for treatment of brainstem glioma with malignant features

Moriya, Shigeta; Ohba, Shigeo; Adachi, Kazuhide; Nishiyama, Yuya; Hayashi, Takuro; Nagahisa, Shinya; Kaito, Takafumi; Nakae, Shunsuke; Hirose, Yuichi

doi:10.1016/j.jocn.2017.10.002

Cited by 12 publications

(7 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…His KPS was 70 at last follow-up, the PFS was over 8 months, and only grade 1 leukopenia and thrombocytopenia were observed; other toxicities for apatinib, such as hypertension, proteinuria, or hand–foot skin reaction, were not developed in our patient. However, among cases that we summarized above in which malignant BSGs were managed with bevacizumab and chemoradiation,20–24 only one patient who was diagnosed by MRI showed disappeared contrast enhancement in the tumor lesion region after treatment 21. Compared to the therapeutic effect with bevacizumab, the treatment response with apatinib in our case was encouraging; although it is only one case, it provides an additional treatment option for malignant BSG.…”

Section: Discussionmentioning

confidence: 58%

“…In recent years, there have been several reports regarding antiangiogenic therapy, such as bevacizumab (an anti-vascular endothelial growth factor monoclonal antibody, which has been intensively studied in recurrent glioblastoma), as an effective salvage therapy for progressive BSG 19. After administering bevacizumab, an improvement in clinical conditions has been shown, along with satisfactory radiologic responses and a progression-free survival (PFS) up to 2 years 20–24. However, the efficacy of first-line antiangiogenic therapy for adult BSG is unknown (Table 3).…”

Section: Discussionmentioning

confidence: 99%

“…Receptor-specific antibodies and small molecular TKIs have been developed for antiangiogenic therapy. Because bevacizumab was most commonly used and reported to be effective in combined antiangiogenic therapy of BSG,20–24 bevacizumab was recommended initially, but the patient refused for financial reasons. Then, we suggested consideration of TKIs (such as sorafenib, pazopanib, sunitinib, or apatinib), which target the vascular endothelial growth factor receptor (VEGFR) 25–29.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

<p>Treatment of adult brainstem glioma with combined antiangiogenic therapy: a case report and literature review</p>

Yu¹,

Hân²,

Liu³

et al. 2019

OTT

View full text Add to dashboard Cite

Adult brainstem gliomas belong to a rare and heterogeneous group of brain tumors. The overall prognosis is poor; therapeutic options are limited, given the resistance to radiotherapy and the unclear role of chemotherapy/antiangiogenic therapy. Apatinib, a tyrosine kinase inhibitor that selectively inhibits the vascular endothelial growth factor receptor and mildly inhibits c-Kit, PDGFR-β, RET, and c-SRC, has been reported to show efficacy among some patients with malignant supratentorial gliomas. However, its effect on brainstem glioma has not been reported so far. Herein, a 66-year-old man with brainstem anaplastic astrocytoma isocitrate dehydrogenase (IDH) wild type was treated initially with combined radiotherapy, temozolomide, and apatinib. The patient achieved a complete response by MRI and continues to have an ongoing progression-free survival of over 8 months. To our knowledge, this is the first case report using apatinib to treat brainstem IDH wild-type anaplastic astrocytoma, displaying an excellent outcome. We also summarize cases of adult brainstem glioma treated with antiangiogenic therapy. Experiences using various regimens may improve understanding of this rare disease, and thus help physicians to seek more effective treatments for these patients.

show abstract

Section: Discussionmentioning

confidence: 58%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

<p>Treatment of adult brainstem glioma with combined antiangiogenic therapy: a case report and literature review</p>

Yu¹,

Hân²,

Liu³

et al. 2019

OTT

View full text Add to dashboard Cite

show abstract

“…Bevacizumab used alone or in combination with cytotoxic chemotherapy in patients had a good performance status at the time of GBM recurrence. However, a few studies do not support the use of bevacizumab to prolong progression-free survival and OS in the primary site of GBMs (Diaz et al, 2017;Moriya et al, 2018). Therefore, to elucidate the key molecules and signaling pathways involved with the expression and function of VEGFs in GBM is of utmost importance.…”

Section: Introductionmentioning

confidence: 99%

Identification of COL6A1 as the Key Gene Associated with Antivascular Endothelial Growth Factor Therapy in Glioblastoma Multiforme

Lin

Yang

Hou

et al. 2021

Genetic Testing and Molecular Biomarkers

View full text Add to dashboard Cite

Background: Vascular endothelial growth factors (VEGFs) are important for glioblastoma multiforme (GBM) growth and development. However, the effects of VEGF-targeting drugs in primary GBM remain poorly understood. Aim: We aimed to explore the key genes correlated with VEGF expression and prognosis and elucidate their potential implications in GBM anti-VEGF therapy. Materials and Methods: RNA-seq data with the corresponding clinicopathological information was retrieved from The Cancer Genome Atlas and the Chinese Glioma Genome Atlas. Weighted gene coexpression network analyses was performed on differentially expressed genes to construct coexpression modules and investigate their correlation with VEGFs. Functional enrichment analyses were performed based on the coexpressed genes from the most promising modules. CytoHubba and Kaplan-Meier analyses were implemented to identify the key genes in the modules of interest. The oncomine database, quantitative reverse transcription PCR, and the Human Protein Atlas were used to investigate the expression characteristics of the identified key genes. Results: Four modules (cyan, green, purple, and tan) correlated significantly with VEGF expression. Enrichment analyses suggested that extracellular matrix-receptor interaction, growth factor binding, and the PI3K-Akt pathways were involved in VEGF expression. Four hub genes (COL6A1, SNRPG, COL3A1, and AHI1) associated with VEGF were identified. Among them, COL6A1 was regarded as the key gene associated with anti-VEGF therapy. Further, COL6A1 was upregulated in GBM compared to that in normal brain tissues. COL6A1 overexpression was associated with a poor prognosis. Conclusion: COL6A1 was identified as the key gene associated with anti-VEGF therapy and may provide novel insight into GBM targeted therapy.

show abstract

“…Unlike many other types of malignant tumor, glioblastoma lacks of effective treatment measures and drug targets (Snape and Warr, 2015;Higashijima and Kanki, 2019;Ruta et al, 2019). Recent phase II/III clinical trials on glioblastoma were all failed, including immune checkpoint inhibitor PD-1 or PD-L1 (Berghoff and Preusser, 2016;Charoentong et al, 2017;Kurz et al, 2018) or anti-angiogenic drugs like bevacizumab (Kurz et al, 2018;Moriya et al, 2018). Life is composed of complicated regulator control system, the cancer happened normally involved in gene mutation, change of epigenetics and gain of fusiongene (Liang et al, 2019).…”

Section: Introductionmentioning

confidence: 99%

Multi-Omics Analysis Reveals Novel Subtypes and Driver Genes in Glioblastoma

et al. 2020

View full text Add to dashboard Cite

Glioblastoma is the most lethal malignant primary brain tumor; nevertheless, there remains a lack of accurate prognostic markers and drug targets. In this study, we analyzed 117 primary glioblastoma patients’ data that contained SNP, DNA copy, DNA methylation, mRNA expression, and clinical information. After the quality of control examination, we conducted the single nucleotide polymorphism (SNP) analysis, copy number variation (CNV) analysis, and infiltrated immune cells estimate. And moreover, by using the cluster of cluster analysis (CoCA) methods, we finally divided these GBM patients into two novel subtypes, HX-1 (Cluster 1) and HX-2 (Cluster 2), which could be co-characterized by 3 methylation variable positions [cg16957313(DUSP1), cg17783509(PHOX2B), cg23432345(HOXA7)] and 15 (PCDH1, CYP27B1, LPIN3, GPR32, BCL6, OR4Q3, MAGI3, SKIV2L, PCSK5, AKAP12, UBE3B, MAP4, TP53BP1, F5, RHOBTB1) gene mutations pattern. Compared to HX-1 subtype, the HX-2 subtype was identified with higher gene co-occurring events, tumor mutation burden (TBM), and poor median overall survival [231.5 days (HX-2) vs. 445 days (HX-1), P-value = 0.00053]. We believe that HX-1 and HX-2 subtypes may make sense as the potential prognostic biomarkers for patients with glioblastoma.

show abstract

A retrospective study of bevacizumab for treatment of brainstem glioma with malignant features

Cited by 12 publications

References 11 publications

<p>Treatment of adult brainstem glioma with combined antiangiogenic therapy: a case report and literature review</p>

<p>Treatment of adult brainstem glioma with combined antiangiogenic therapy: a case report and literature review</p>

Identification of COL6A1 as the Key Gene Associated with Antivascular Endothelial Growth Factor Therapy in Glioblastoma Multiforme

Multi-Omics Analysis Reveals Novel Subtypes and Driver Genes in Glioblastoma

Contact Info

Product

Resources

About